ORMP revenueQ4 2025$0
ORMP revenue was $0 in fiscal Q4 2025 (ended Dec 31, 2025). For the full fiscal 2025 it was $2.00M.
Oramed Pharmaceuticals Inc. (ORMP) financials
For fiscal 2025 (ended Dec 31, 2025), Oramed Pharmaceuticals Inc. reported $2.00M of revenue and $64.05M of net income.
- Revenue, FY2025
- $2.00M
- Net income, FY2025
- $64.05M
- Net margin
- 3202.5%
- Free cash flow, FY2025
- -$9.15M
- EPS, diluted, FY2025
- $1.50
- Cash
- $15.24M
- P/E
- 2.60
- P/S
- 83.19
- Market cap
- $166.4M
FY2016FY2025
FY2016FY2025
FY2016FY2025
ORMP revenue and earnings growth
ORMP net incomeQ2 2026$78.16M
- Quarter YoY
- +488.2%
- QoQ
- +104.0%
ORMP net income was $78.16M in fiscal Q2 2026 (ended Jun 30, 2026), up 488.2% from a year earlier and up 104.0% from the prior quarter. For the full fiscal 2025 it was $64.05M, compared with -$19.06M in fiscal 2024. Fiscal 2025 is the highest of the 15 fiscal years on file.
ORMP EPSQ2 2026$1.84
- Quarter YoY
- +493.5%
- QoQ
- +102.2%
ORMP diluted EPS was $1.84 in fiscal Q2 2026 (ended Jun 30, 2026), up 493.5% from a year earlier and up 102.2% from the prior quarter. For the full fiscal 2025 it was $1.50, compared with -$0.48 in fiscal 2024.
ORMP free cash flowQ2 2026-$202.0K
ORMP free cash flow was -$202.0K in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$3.54M a year earlier. For the full fiscal 2025 it was -$9.15M, compared with -$8.43M in fiscal 2024.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Aug 31, 2021 | Aug 31, 2020 | Aug 31, 2019 | Aug 31, 2018 | Aug 31, 2017 | Aug 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.00M | - | $1.34M | $2.70M | $2.70M | $2.71M | $2.70M | $2.45M | $2.46M | $641.0K |
| Cost of revenue | $1.99M | - | - | - | - | - | $90.0K | -$86.0K | $187.0K | $490.0K |
| Gross profit | $13.0K | - | - | - | - | - | $2.61M | $2.54M | $2.27M | $151.0K |
| Research and development | $6.38M | $6.32M | $8.97M | $27.64M | $20.99M | $10.23M | $13.52M | $11.98M | $10.28M | $7.71M |
| Selling, general and admin | $8.72M | $6.46M | $8.43M | $13.81M | $5.94M | $4.23M | $3.72M | $4.08M | $2.76M | $2.45M |
| Operating income | -$15.09M | -$12.78M | -$15.77M | -$40.60M | -$24.22M | -$11.76M | -$14.63M | -$13.53M | -$10.77M | -$10.01M |
| Interest expense | - | $853.0K | $2.04M | - | - | - | - | - | - | - |
| Pre-tax income | $75.32M | -$15.92M | $5.09M | -$37.66M | - | -$11.51M | -$14.05M | -$12.73M | -$10.08M | -$9.63M |
| Income tax | $11.31M | $3.18M | - | $100.0K | - | - | $300.0K | - | $400.0K | $1.33M |
| Net income | $64.05M | -$19.06M | $5.09M | -$36.56M | -$22.99M | -$11.51M | -$14.36M | -$12.73M | -$10.48M | -$10.96M |
| EPS, basic | $1.53 | -$0.48 | $0.14 | -$0.94 | $0.78 | $0.56 | $0.82 | $0.86 | $0.79 | $0.87 |
| EPS, diluted | $1.50 | -$0.48 | $0.14 | -$0.94 | $0.78 | $0.56 | $0.82 | $0.86 | $0.79 | $0.87 |
| Diluted shares | 42.4M | 40.9M | 40.6M | 39.0M | 28.5M | 20.5M | 17.5M | 14.9M | 13.3M | 12.6M |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Aug 31, 2021 | Aug 31, 2020 | Aug 31, 2019 | Aug 31, 2018 | Aug 31, 2017 | Aug 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $45.95M | $54.42M | $9.05M | $40.46M | $77.25M | $19.30M | $3.33M | $5.00M | $3.97M | $3.91M |
| Short-term investments | $5.42M | $3.44M | $57.71M | $3.74M | $5.85M | $3.30M | $3.70M | $4.59M | $2.86M | $2.85M |
| Current assets | $133.27M | $143.22M | $162.58M | $157.11M | $95.34M | $40.51M | $33.32M | $31.04M | $20.30M | $31.23M |
| Total assets | $230.86M | $155.28M | $220.55M | $161.64M | $128.00M | $44.63M | $34.66M | $47.40M | $38.71M | $42.83M |
| Current liabilities | $19.09M | $5.68M | $53.21M | $5.75M | $6.68M | $4.54M | $5.31M | $4.55M | $5.17M | $3.62M |
| Short-term debt | - | - | $51.01M | - | - | - | $2.70M | $2.45M | - | - |
| Total debt | - | - | - | $25.0K | $12.54M | - | $9.66M | $11.39M | - | - |
| Total liabilities | $31.12M | $9.93M | $57.66M | $10.49M | $11.48M | $11.75M | $15.27M | - | - | - |
| Shareholders' equity | $199.74M | $145.35M | $162.89M | $151.16M | $116.52M | $32.88M | $19.39M | $31.11M | $19.24M | $26.19M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Aug 31, 2021 | Aug 31, 2020 | Aug 31, 2019 | Aug 31, 2018 | Aug 31, 2017 | Aug 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$9.14M | -$8.41M | -$10.29M | -$27.92M | -$21.18M | -$12.44M | -$12.94M | -$14.66M | -$5.83M | $4.66M |
| Capital expenditures | $9.0K | $18.0K | $254.0K | $496.0K | $375.0K | $82.0K | $15.0K | $5.0K | $7.0K | $9.0K |
| Free cash flow | -$9.15M | -$8.43M | -$10.55M | -$28.41M | -$21.56M | -$12.52M | -$12.96M | -$14.66M | -$5.84M | $4.65M |
| Investing cash flow | $5.44M | $105.82M | -$73.04M | $30.21M | -$23.76M | $4.63M | $11.26M | -$7.00M | $4.30M | -$16.01M |
| Financing cash flow | -$4.74M | -$52.04M | $51.98M | $10.78M | $102.89M | $23.79M | - | $22.65M | $1.59M | $12.04M |
| Share repurchases | $4.74M | $2.48M | - | - | - | - | - | - | - | - |
| Stock-based compensation | $5.99M | $4.05M | $4.21M | $11.51M | $2.69M | $465.0K | $808.0K | $1.55M | $1.57M | $634.0K |
Key ratios
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Aug 31, 2021 | Aug 31, 2020 | Aug 31, 2019 | Aug 31, 2018 | Aug 31, 2017 | Aug 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | - | - | -50.4% | 0.0% | -0.3% | 0.3% | 10.4% | -0.3% | 283.2% | - |
| EPS growth, YoY | - | - | - | - | 39.3% | -31.7% | -4.7% | 8.9% | -9.2% | 29.9% |
| Gross margin | 0.7% | - | - | - | - | - | 96.7% | 103.5% | 92.4% | 23.6% |
| Operating margin | -754.4% | - | -1176.8% | -1502.0% | -896.2% | -433.8% | -541.3% | -552.3% | -438.6% | -1561.6% |
| Net margin | 3202.5% | - | 379.7% | -1352.6% | -850.5% | -424.8% | -531.1% | -519.7% | -426.7% | -1710.5% |
| Free cash flow margin | -457.7% | - | -787.2% | -1051.2% | -797.5% | -462.1% | -479.3% | -598.7% | -237.7% | 724.8% |
| Return on equity | 32.1% | -13.1% | 3.1% | -24.2% | -19.7% | -35.0% | -74.0% | -40.9% | -54.5% | -41.9% |
| Return on assets | 27.7% | -12.3% | 2.3% | -22.6% | -18.0% | -25.8% | -41.4% | -26.9% | -27.1% | -25.6% |
| Current ratio | 6.98 | 25.19 | 3.06 | 27.34 | 14.27 | 8.93 | 6.28 | 6.82 | 3.93 | 8.62 |
| Debt to equity | - | - | - | 0.00 | 0.11 | - | 0.50 | 0.37 | - | - |
Income statement
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | $0 | $0 | $0 | $2.00M | - | - | - | - | $0 | $0 |
| Cost of revenue | - | - | $0 | $0 | $0 | $1.99M | - | - | - | - | - | - |
| Gross profit | - | - | $0 | $0 | $0 | $13.0K | - | - | - | - | - | - |
| Research and development | $0 | $1.59M | $1.99M | $1.15M | $1.03M | $2.21M | $1.46M | $2.24M | $1.44M | $1.18M | $1.77M | $957.0K |
| Selling, general and admin | $2.77M | $2.06M | $3.68M | $1.27M | $1.46M | $2.31M | $2.13M | $847.0K | $1.69M | $1.78M | $2.11M | $2.60M |
| Operating income | -$2.77M | -$3.66M | -$5.67M | -$2.43M | -$2.49M | -$4.50M | -$3.60M | -$3.09M | -$3.13M | -$2.96M | -$3.88M | -$2.89M |
| Interest expense | - | - | - | - | - | - | $0 | $0 | $261.0K | $592.0K | $1.21M | $826.0K |
| Pre-tax income | $101.59M | $49.44M | $9.80M | $59.45M | $13.13M | -$7.06M | -$9.78M | -$18.51M | $10.84M | $1.53M | $13.30M | -$3.28M |
| Income tax | $23.43M | $11.13M | -$212.0K | $11.06M | -$126.0K | $584.0K | $416.0K | $1.13M | $1.63M | $0 | - | - |
| Net income | $78.16M | $38.31M | $10.01M | $48.40M | $13.29M | -$7.64M | -$10.19M | -$19.62M | $9.21M | $1.54M | $12.90M | -$3.22M |
| EPS, basic | $1.90 | $0.94 | $0.24 | $1.16 | $0.32 | -$0.19 | -$0.26 | -$0.48 | $0.22 | $0.04 | $0.33 | -$0.08 |
| EPS, diluted | $1.84 | $0.91 | $0.25 | $1.13 | $0.31 | -$0.19 | -$0.26 | -$0.48 | $0.22 | $0.04 | $0.33 | -$0.08 |
| Diluted shares | 42.5M | 42.0M | - | 42.8M | 42.6M | 41.2M | - | 40.9M | 41.6M | 41.6M | - | 40.4M |
Balance sheet
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $15.24M | $13.20M | $45.95M | $52.18M | $15.80M | $74.52M | $54.42M | $42.10M | $84.75M | $18.58M | $9.05M | $5.47M |
| Short-term investments | $846.0K | $4.96M | $5.42M | $4.96M | $1.75M | $3.69M | $3.44M | $57.45M | $66.21M | $77.73M | $57.71M | $49.4K |
| Current assets | $53.41M | $68.15M | $133.27M | $136.12M | $99.03M | $131.48M | $143.22M | $142.77M | $153.27M | $177.09M | $162.58M | $175.71M |
| Total assets | $369.64M | $268.85M | $230.86M | $220.49M | $161.68M | $147.54M | $155.28M | $165.08M | $184.22M | $203.65M | $220.55M | $230.89M |
| Current liabilities | $10.73M | $10.56M | $19.09M | $6.12M | $3.69M | $5.49M | $5.68M | $5.27M | $3.73M | $33.56M | $53.21M | $78.17M |
| Short-term debt | - | - | - | - | - | - | - | - | - | $32.03M | $51.01M | $75.36M |
| Total debt | - | - | - | - | - | - | - | - | - | - | - | $74.55M |
| Total liabilities | $52.17M | $30.57M | $31.12M | $18.16M | $8.10M | $7.64M | $9.93M | $9.56M | $8.07M | $37.93M | $57.66M | $82.66M |
| Shareholders' equity | $317.47M | $238.28M | $199.74M | $203.28M | $153.58M | $139.89M | $145.35M | $155.52M | $176.15M | $165.72M | $162.89M | $148.23M |
Cash flow
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$200.0K | -$2.92M | -$466.0K | -$1.63M | -$3.54M | -$3.52M | -$1.91M | -$7.10M | $2.08M | -$1.48M | -$1.42M | -$694.0K |
| Capital expenditures | $2.0K | $5.0K | $2.0K | $0 | $4.0K | $3.0K | $11.0K | $5.0K | $0 | $2.0K | $3.0K | $32.0K |
| Free cash flow | -$202.0K | -$2.92M | -$468.0K | -$1.63M | -$3.54M | -$3.52M | -$1.92M | -$7.11M | $2.08M | -$1.48M | -$1.42M | -$726.0K |
| Investing cash flow | $4.31M | -$19.49M | -$1.68M | $38.36M | -$54.85M | $23.62M | $15.42M | -$34.26M | $94.66M | $30.00M | $30.00M | -$75.12M |
| Financing cash flow | -$1.95M | -$10.36M | -$4.01M | -$361.0K | - | - | -$1.20M | -$1.29M | -$30.55M | -$19.00M | -$25.00M | $74.55M |
| Dividends paid | $78.0K | $10.36M | - | - | - | - | - | - | - | - | - | - |
| Share repurchases | - | - | $4.01M | $361.0K | - | - | $1.19M | - | - | - | - | - |
| Stock-based compensation | $1.39M | $1.74M | $2.28M | $719.0K | $800.0K | $2.19M | $1.23M | $301.0K | $1.23M | $1.29M | $1.37M | $852.0K |
Key ratios
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | - | - | - | - | - | - | - | - | - | - | -100.0% | -100.0% |
| Net income growth, YoY | 488.2% | - | - | - | 44.2% | - | - | - | - | - | - | - |
| EPS growth, YoY | 493.5% | - | - | - | 40.9% | - | - | - | - | - | - | - |
| Gross margin | - | - | - | - | - | 0.7% | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | -225.0% | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | -382.1% | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | -176.1% | - | - | - | - | - | - |
| Current ratio | 4.98 | 6.45 | 6.98 | 22.24 | 26.81 | 23.94 | 25.19 | 27.08 | 41.06 | 5.28 | 3.06 | 2.25 |
| Debt to equity | - | - | - | - | - | - | - | - | - | - | - | 0.50 |
Source: XBRL data Oramed Pharmaceuticals Inc. files with the SEC, latest filing dated Aug 10, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
ORMP peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| ORMP | $2.00M | - | $64.05M | 3202.5% | $166.4M |
| LLY | $86.46B | +45.5% | $27.58B | 31.9% | $1.33T |
| JNJ | $99.33B | +7.8% | $16.09B | 16.2% | $679.13B |
| ABBV | $66.01B | +10.7% | $10.34B | 15.7% | $518.44B |
| MRK | $67.38B | +4.9% | $2.45B | 3.6% | $366.73B |
| NVS | $54.53B | +8.4% | $13.98B | 25.6% | $312.35B |
| AZN | $58.74B | +8.6% | $10.22B | 17.4% | $293.69B |
| ABT | $48.23B | +10.0% | $4.70B | 9.7% | $191.40B |
| NVO | DKK 309.06B | +6.4% | DKK 102.43B | 33.1% | $183.23B |
ORMP FAQ
8 questionsWhat is ORMP revenue?
Oramed Pharmaceuticals Inc. (ORMP) reported $2.00M of revenue for fiscal 2025 (ended Dec 31, 2025).Is ORMP profitable?
Yes. Oramed Pharmaceuticals Inc. earned $64.05M in net income for fiscal 2025 (ended Dec 31, 2025), a net margin of 3202.5%.How much cash and debt does ORMP have?
Oramed Pharmaceuticals Inc. reported $15.24M in cash and cash equivalents on its most recent balance sheet in SEC filings.What is ORMP gross margin?
Oramed Pharmaceuticals Inc.'s gross profit was $13.0K on $2.00M of revenue for fiscal 2025 (ended Dec 31, 2025), a gross margin of 0.7%.What is ORMP free cash flow?
Oramed Pharmaceuticals Inc. generated -$9.15M of free cash flow for fiscal 2025 (ended Dec 31, 2025), which is operating cash flow of -$9.14M less capital expenditures.What is ORMP earnings per share?
Diluted earnings per share were $1.50 for fiscal 2025 (ended Dec 31, 2025), from SEC filings, restated for any stock split those filings show.When did ORMP last report financial results?
The latest statements here come from Oramed Pharmaceuticals Inc.'s 10-Q filed on Aug 10, 2026, covering the period ended Jun 30, 2026.Where does this ORMP financial data come from?
Quantisnow builds these statements from the structured XBRL data Oramed Pharmaceuticals Inc. files with the SEC. It is provided for information only and is not investment advice.